12 replies to this topic

[Jacovis]

Some of the products with EPA-only formulas that qualify for this thread are as follows...


http://www.aor.ca/in...s/epa_brite.php

AOR EPA Brite

90 Softgels 325 mg AOR04117
180 Softgels 325 mg AOR04076
______________________________________________
SUPPLEMENT FACTS:
Serving Size: 1 Softgel
____________________________________________________
Eicosapentaenoic Acid (EPA) ............ 325 mg
Docosahexaenoic Acid (DHA) .......... < 0.1 mg
____________________________________________________

Other ingredients: silicon dioxide, mixed tocopherols, rosemary oil. Capsule: gelatin, water and glycerin. Source for fish oil: Anchovy.


http://vegepa.com/ve...amp;ti=Products
Vegepa
Each Vegepa capsule contains:
280 mg ultra-pure EPA (omega-3) from marine fish oil
100 mg organic virgin evening primrose oil (containing omega-6)
1 mg vitamin E (anti-oxidant)
The outer capsule shell contains fish gelatine.


http://www.biovita.f...teet/e-epa.html
E-EPA 500 mg (70%)
E-EPA 650 mg (90%)

Dr Tolonen's Ethyl EPA, an ultra pure dietary supplement rich in Omega-3 fatty acid EPA; 70 %, alternatively 90 %. Unmatched in strength and purity when compared to other omega-3 products.
60 or 120 softgel capsules
2 or 4 months supply in hygienic blisters.
These capsules consist of a total of 714 mg fish oil, out of which pure E-EPA either 70% (500mg ) or 90% (650mg). The latter version is the most highly concentrated EPA product available in Europe.
E-EPA is a unique refined fish oil preparation, ethyl ester of the eicosapentaeonic acid (EPA), which from research is believed to be superior to all other conventional Omega-3 products. Each capsule contains the amazing amount of 70 % (500 mg), alternatively 90 % (650 mg), pure vacuum destilled E-EPA plus vitamin E as antioxidant and 5 µg vitamin D. Conventional omega-3´s contain only 15 to 35 % EPA. A typical fish oil capsule sold in stores contains 1000 mg of fish oil of which only 180 mg is EPA and 120 mg is DHA. The other 700 mg are other oils not known to be of benefit (on the contrary).

[Jacovis]

Series of recent studies coming out of Melbourne, Australia using Ethyl-EPA in the treatment of first-episode psychosis...

1: J Clin Psychiatry. 2007 Dec;68(12):1867-75. Links
Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial.Berger GE, Proffitt TM, McConchie M, Yuen H, Wood SJ, Amminger GP, Brewer W, McGorry PD.
ORYGEN Research Centre (incorporating the Early Psychosis Prevention and Intervention Centre [EPPIC]), University of Melbourne, Australia. bergerg@mac.com

OBJECTIVE: To investigate if ethyl-eicosapentaenoic acid (E-EPA) augmentation improves antipsychotic efficacy and tolerability in first-episode psychosis (FEP). METHOD: We performed a 12-week, randomized, double-blind, placebo-controlled trial of 2-g E-EPA augmentation in 80 FEP patients. Sixty-nine patients were eligible for analysis; a post hoc analysis was computed for a subgroup of nonaffective FEP patients (N = 53). The first participant was included in November 2000 and the last participant completed the trial in August 2003. Primary outcome measures were symptom change scores and time to first response, while tolerability measures and cumulative antipsychotic dose were secondary outcome measures. RESULTS: Analysis of covariance controlling for baseline symptoms found no significant mean difference between E-EPA and placebo at week 12 for symptom change scores. Cox regression analysis revealed a significant treatment by diagnosis interaction (p = .024) for time to first response favoring E-EPA in nonaffective psychosis. Post hoc analysis for cumulative response rates further confirmed a higher response rate at week 6 (42.9% [15/35] vs. 17.6% [6/34] for all participants, p = .036; 54.2% [13/24] vs. 17.2% [5/29] for the nonaffective psychosis subset, p = .008); however, the difference at week 12 was no longer significant. Analysis of secondary outcome measures revealed that E-EPA-augmented participants needed 20% less antipsychotic medication between weeks 4 through 6 (p = .03), had less extrapyramidal side effects in the initial 9 weeks (p < .05 for all participants and for all timepoints), and reported less constipation (p = .011) and fewer sexual side effects (p = .016) than those treated with antipsychotic medication alone. CONCLUSION: The findings suggest that E-EPA may accelerate treatment response and improve the tolerability of antipsychotic medications. However, it was not possible to demonstrate a sustained symptomatic benefit of E-EPA in early psychosis, possibly due to a ceiling effect, since a high proportion of first-episode patients already achieve symptomatic remission with antipsychotic medication alone. Further controlled trials in nonaffective early psychosis seem warranted. TRIAL REGISTRATION: Australian Clinical Trials Registry identifier 12605000267651 (http://actr.org.au).

PMID: 18162017 [PubMed - indexed for MEDLINE]


1: Neuropsychopharmacology. 2008 Jan 16. [Epub ahead of print] Links
Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study.Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP, Jackson GD, Velakoulis D, Pantelis C, McGorry PD.
[1] 1Department of Psychiatry, ORYGEN Research Centre, University of Melbourne, Parkville, Australia [2] 2Department of Research & Education, The Schloessli Clinic, Oetwil am See, Zuerich, Switzerland [3] 3Howard Florey Institute, The University of Melbourne, Parkville, Australia.

Ethyl-eicosapentaenoic acid (E-EPA) is an omega-3 fatty acid that has been used in a range of neuropsychiatric conditions with some benefits. However, its mechanism of action is unknown. Here, we investigate its effects on in vivo brain metabolism in first-episode psychosis (FEP). Proton magnetic resonance spectroscopy at 3 T was performed in the temporal lobes of 24 FEP patients before and after 12 weeks of treatment in the context of a larger double-blind, placebo-controlled E-EPA augmentation study. Treatment group effects for glutathione (F1,12=6.1, p=0.03), and a hemisphere-by-group interaction for glutamine/glutamate (F1,20=4.4, p=0.049) were found. Glutathione increased bilaterally and glutamate/glutamine increased in the left hemisphere following E-EPA administration. Improvement in negative symptoms correlated with metabolic brain changes, particularly glutathione (r=-0.57). These results suggest that E-EPA augmentation alters glutathione availability and modulates the glutamine/glutamate cycle in early psychosis, with some of the metabolic brain changes being correlated with negative symptom improvement. Larger confirmatory studies of these postulated metabolic brain effects of E-EPA are warranted.Neuropsychopharmacology advance online publication, 16 January 2008; doi:10.1038/sj.npp.1301628.

PMID: 18199999 [PubMed - as supplied by publisher]


1: Neuropsychopharmacology. 2008 May 21. [Epub ahead of print] Links
Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study.Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP, Jackson GD, Velakoulis D, Pantelis C, McGorry PD.
PMID: 18496523 [PubMed - as supplied by publisher]

[Jacovis]

Studies of Ethyl-EPA in the treatment of Huntington disease...

1: Neuroreport. 2002 Jan 21;13(1):123-6. Links
MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment.Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, Appel C, Mckee HM, Vaddadi KS, Horrobin DF.
Magnetic Resonance Unit, MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, London UK.

A 6-month randomized, placebo-controlled pilot study of the ethyl-ester of eicosapentaenoic acid (ethyl-EPA) was carried out in seven in-patients with advanced (stage III) Huntington's disease (three on ethyl-EPA, four on placebo; no significant difference in age or sex between the groups). After 6 months all the patients treated with ethyl-EPA improved on the orofacial component of the Unified Huntington's Disease Rating Scale while all the patients on placebo deteriorated on this scale (p < 0.03). Following subvoxel registration of follow-up 3D MRI brain scans with baseline scans, subtraction images showed that while the placebo was associated with progressive cerebral atrophy, the ethyl-EPA was associated with a reverse process. We conclude that treatment with ethyl-EPA is associated with beneficial motor and MRI changes.

PMID: 11924873 [PubMed - indexed for MEDLINE]


1: Neurology. 2005 Jul 26;65(2):286-92. Links
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H.
Imaging Sciences Department, MRC Clinical Sciences Centre, Imperial College, Hammersmith Hospital, London, UK.

BACKGROUND: Preliminary evidence suggests beneficial effects of pure ethyl-eicosapentaenoate (ethyl-EPA) in Huntington disease (HD). METHODS: A total of 135 patients with HD were randomized to enter a multicenter, double-blind, placebo-controlled trial on the efficacy of 2 g/d ethyl-EPA vs placebo. The Unified Huntington's Disease Rating Scale (UHDRS) was used for assessment. The primary end point was outcome at 12 months on the Total Motor Score 4 subscale (TMS-4). Analysis of covariance (ANCOVA) and a chi2 test on response, defined as absence of increase in the TMS-4, were performed. RESULTS: A total of 121 patients completed 12 months, and 83 did so without protocol violations (PP cohort). Intent-to-treat (ITT) analysis revealed no significant difference between ethyl-EPA and placebo for TMS-4. In the PP cohort, ethyl-EPA proved better than placebo on the chi2 test on TMS-4 (p < 0.05), but missed significance on ANCOVA (p = 0.06). Secondary end points (ITT cohort) showed no benefit of ethyl-EPA but a significantly worse outcome in the behavioral severity and frequency compared with placebo. Exploring moderators of the efficacy of ethyl-EPA on TMS-4 showed a significant interaction between treatment and a factor defining patients with high vs low CAG repeats. Reported adverse events were distributed equally between treatment arms. CONCLUSIONS: Ethyl-eicosapentaenoate (ethyl-EPA) (purity > 95%) had no benefit in the intent-to-treat cohort of patients with Huntington disease, but exploratory analysis revealed that a significantly higher number of patients in the per protocol cohort, treated with ethyl-EPA, showed stable or improved motor function. Further studies of the potential efficacy of ethyl-EPA are warranted.

PMID: 16043801 [PubMed - indexed for MEDLINE]


1: Exp Neurol. 2005 Dec;196(2):266-72. Epub 2005 Aug 29. Links
Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR.
Department of Medical Genetics and Centre for Molecular Medicine and Therapeutics, British Columbia Research Institute for Children's and Women's Health, University of British Columbia, 980 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4.

Huntington disease (HD) is an adult-onset neurodegenerative disorder that is characterized by selective degeneration in the striatum. There are currently no treatments that can prevent the progressive decline of motor and cognitive function in HD. In parallel with a human clinical trial, we examined the efficacy of ethyl-EPA treatment in the YAC128 mouse model of HD. Oral delivery of ethyl-EPA to symptomatic YAC128 mice beginning at 7 months of age increased membrane EPA levels 3-fold (P < 0.001) and resulted in a modest but significant improvement in motor dysfunction by 12 months of age as measured by open-field activity (P = 0.01) and performance on the rotarod (P = 0.05). At this age, ethyl-EPA-treated YAC128 mice showed no improvement in striatal volume, striatal neuron counts, striatal neuronal cross-sectional area, or striatal DARPP-32 expression compared to untreated YAC128 mice, thereby indicating no reduction of striatal neuropathology. This result is congruent with modest motor benefits observed in HD patients treated with ethyl-EPA. Overall, this work demonstrates the feasibility of experimental therapeutics in the YAC128 mouse model and suggests that experiments in these mice may be predictive for future human clinical trials.

PMID: 16129433 [PubMed - indexed for MEDLINE]


1: Brain Res Bull. 2007 Apr 30;72(2-3):159-64. Epub 2006 Nov 15. Links
Ethyl-EPA in Huntington disease: potentially relevant mechanism of action.Murck H, Manku M.
Amarin Neuroscience Ltd, Laurelhill Business Park, Stirling, UK. hmurck@amarin-neuro.com

The pathomechanisms involved in the neuronal dysfunction in Huntington disease (HD) are still unresolved and may be heterogeneous. One potential mechanism might be related to the induction of mitochondrial dysfunction in the CNS. This might lead firstly to neuronal dysfunction and finally to the activation of apoptotic pathways. Several compounds, which should alleviate mitochondrial dysfunction, have been tested in preclinical models as well as in clinical trials of different scale. Recently we reported the efficacy of Ethyl-eicosapentaenoic acid (Ethyl-EPA) in patients with HD. Ethyl-EPA is a polyunsaturated fatty acid from the n-3 group, which is in clinical development for HD and melancholic depression. In our trial with Ethyl-EPA in HD responding patients could be characterized by either a lower CAG repeat number or a chorea-predominant clinical expression of the disease. Here we would like to describe some evidence on the potential mechanism of action of Ethyl-EPA in HD. We specifically focus on pathways, which are known to be influenced in HD and are modified by Ethyl-EPA and which points to an involvement of mitochondrial function as a common target. Some attention is given to the NF-kappa B pathway and the c-Jun amino-terminal kinases (JNK) pathway, which both may lead to an activation of the antiproliferative factor p53 and consequently mitochondrial dysfunction. Further the effects of EPA or Ethyl-EPA in preclinical models of HD are described. The evidence from these studies led to the design of phase III clinical trials, which are ongoing.

PMID: 17352940 [PubMed - indexed for MEDLINE]

Edited by Visionary7903, 14 June 2008 - 05:19 AM.

[Jacovis]

Ethyl EPA in the treatment of borderline personality disorder...

1: Am J Psychiatry. 2003 Jan;160(1):167-9. Links
omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.Zanarini MC, Frankenburg FR.
Laboratory for the Study of Adult Development, McLean Hospital, Belmont, MA 02478, USA. zanarini@mclean.harvard.edu

OBJECTIVE: The purpose of this study was to compare the efficacy of ethyl-eicosapentaenoic acid (E-EPA) and placebo in the treatment of female subjects with borderline personality disorder. METHOD: The authors conducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meeting Revised Diagnostic Interview for Borderlines and DSM-IV criteria for borderline personality disorder. RESULTS: Twenty subjects were randomly assigned to 1 g of E-EPA; 10 subjects were given placebo. Ninety percent of those in both groups completed all 8 weeks of the trial. Analyses that used random-effects regression modeling and controlled for baseline severity showed E-EPA to be superior to placebo in diminishing aggression as well as the severity of depressive symptoms. CONCLUSIONS: The results of this study suggest that E-EPA may be a safe and effective form of monotherapy for women with moderately severe borderline personality disorder.

PMID: 12505817 [PubMed - indexed for MEDLINE]

[ortcloud]

Some of the products with EPA-only formulas that qualify for this thread are as follows...

There is one other brand you forgot. I have been taking it for a year or so.

http://www.iherb.com...573725057314996

PlusEPA

90% EPA 500mg. per cap

[Jacovis]

Some of the products with EPA-only formulas that qualify for this thread are as follows...

There is one other brand you forgot. I have been taking it for a year or so.

http://www.iherb.com...573725057314996

PlusEPA

90% EPA 500mg. per cap

Thanks ortcloud. Minami Nutrition's PlusEPA looks like exactly the kind of product this thread is all about:

Supplement Facts
Supplement Facts
Serving Size: 2 Softgels
Servings Per Container: 30
Amount Per Serving % DV
Calories 12
Calories from Fat 10
Total Fat 1.11 g 1.7%
Saturated fat 0 mg 0%
Cholesterol 0 mg 0%
Total Carbohydrate 0 g 0%
Total Protein 0.4 g 0.8%
Omega-3 Polyunsaturated Fat 1032 mg
EPA (Eicosapentaenoic Acid) 1000 mg †
DHA (Docosahexaenoic Acid) 0 mg †
Other Omega-3 Fatty Acids 32 mg †
Omega-6 Polyunsaturated Fat 32 mg †
Vitamin E (mixed tocopherols) 22 mg 146%
*Percent daily values based on 2,000 calorie diet.
†Daily value not established.

Other Ingredients
Pharmaceutical-grade deep-sea fish oil, hard capsule (gelatin, purified water, glycerol), Antioxidant (mixed tocopherols).

Pure and natural products without use of solvents or chemicals such as hexane.

The following reviews (for what their worth!) look ok as well for this product:
http://www.iherb.com...573725057314996
Works!, December 11, 2007
By Alex Epshteyn from United States NY
Love the stuff, never any taste and I can feel the difference after 2 weeks.
Note: iHerb does not imply any medical claims from this review. Disclaimer
ADHD, January 04, 2008
from United States CA
Works great ! Only product of its kind ! Highest EPA percentage ! There is a slight aftertaste, but not too much to make it a great concern. After trying many products of this kind, this is the best and they use a cold distillation process as opposed to exposing the product to high heat.
Note: iHerb does not imply any medical claims from this review. Disclaimer

http://www.amazon.co...3/dp/B000K7QJVW
Lynne, February 28, 2008
By Lynne E. Hogg (Orlando, Florida) - See all my reviews
This is an excellent product. My son has ADD Inattentive type and he takes 2 capsules every day, along with his medication, to improve his concentration. With the highest concentration of Omega 3, you will not find better.

[gn1tmac]

EPA ethyl ester

Ethyl ester concentrates (E-EPA) are produced by reacting crude fish oil with ethanol under vacuum, heat distilled to separate the volatile component, the omega-3 ethyl ester. The resulting condensate is a concentrated omega-3 ethyl ester solution. The concentration of the omega-3 fatty acids depends on the variables of the distillation process but normally results in a 70–90% EPA solution.

Indirectly/directly it may:


-improve fatty acid metabolism and energetics in muscle (fat loss)

-reverses many of the metbolic issues of insulin resistance and type II diabetes

-slow down ubinquination of cells and impedes less lysis (hypertrophic growth is more cells added over those broken down).

-cause neuronal repair

-it can be tranported and can even cross the blood brain barrier, also acts protectively on long axon neurons in the spinal column.

-been shown to help ALS (Lou Gehrigs disease)

-shown to be effective in liver lipid control (cholesterol control agent).

-control myoblast (early myocyte) diffeentiation*

-upregulate cell production and slow down cell turnover*

* I believe the last two are related to EPA EE and its effect (change) on IL-6 and its role in mytostatin controls. The process of IL-6 control seems to be tied to control of oxidative damage in the cells resulting from improved fatty acid metabolism and the oxygen free radicals that result. I don't completely understand how this occurs but if someone wants to talk cell theory we can discuss how this might work.

[Jacovis]

And a couple of studies using Ethyl-EPA (one in Alzheimer's disease and one in tardive dyskinesia) in which the results weren't so clear cut...

1: Prostaglandins Leukot Essent Fatty Acids. 2004 Nov;71(5):341-6.
Ethyl-EPA in Alzheimer's disease--a pilot study.
Boston PF, Bennett A, Horrobin DF, Bennett CN.
Michael Carlisle Centre, Nether Edge Hospital, 75 Osborne Road, Sheffield, S. Yorks S11 9BF, UK. p.boston@shef.ac.uk

This pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in the treatment of Alzheimer's disease aimed to estimate the magnitude of any change in measures of cognition during a 12-week treatment period. A simple linear design was used in which each patient had a baseline period of 12 weeks without treatment, followed by 12 weeks' treatment with ethyl-EPA. Blood samples were taken both before and after the treatment period to measure erythrocyte membrane fatty acids. Assessments comprised cognitive measures and visual analogue ratings of overall assessment of functioning. There was little difference between treatment and baseline periods in the rate of decline of efficacy measures, except for a small improvement in carer's visual analogue rating (P=0.02). It was concluded that it is unlikely there were any clinically important treatment effects of ethyl-EPA on cognition during the 12-week treatment period. A longer treatment period may be necessary to demonstrate efficacy of ethyl-EPA in this disorder.

PMID: 15380822 [PubMed - indexed for MEDLINE]


1: Schizophr Res. 2006 May;84(1):112-20. Epub 2006 Apr 24.
The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.
Emsley R, Niehaus DJ, Koen L, Oosthuizen PP, Turner HJ, Carey P, van Rensburg SJ, Maritz JS, Murck H.
Department of Psychiatry, Faculty of Health Sciences, University of Stellenbosch, PO Box 19063, Tygerberg 7505, Cape Town, South Africa. rae@sun.ac.za

OBJECTIVE: Worldwide, conventional antipsychotic medication continues to be used extensively, and tardive dyskinesia (TD) remains a serious complication. The primary objective of the present study was to compare the efficacy of EPA versus placebo in reducing symptoms of TD. METHOD: This was a 12-week, double-blinded, randomized study of ethyl-EPA 2g/day versus placebo as supplemental medication, in patients with schizophrenia or schizoaffective disorder, with established TD. RESULTS: Eighty-four subjects were randomized, of whom 77 were included in the analysis. Both the EPA and placebo groups displayed significant baseline to endpoint improvements in Extrapyramidal Symptom Rating Scale dyskinesia scores, but there were no significant between-group differences (p=0.4). Response rates (>or=30% improvement in TD symptoms) also did not differ significantly between EPA-treated subjects (45%) and placebo-treated subjects (32%) (p=0.6). However, a post-hoc linear mixed model repeated measures analysis of variance indicated an effect for treatment group and duration of TD. The EPA-treated patients had significantly greater mean reductions in dyskinesia scores initially, although this was not sustained beyond 6 weeks. CONCLUSIONS: This trial failed to demonstrate an anti-dyskinetic effect for ethyl-EPA 2g/day on the primary efficacy measure. However, a modest and transient benefit is suggested in patients with more recent onset of TD. The lack of clear-cut efficacy could be explained on the basis of the dose of EPA being too low, the study being underpowered, TD being too chronic in the majority of cases, differences in dietary fatty acid intake, or that EPA lacks an anti-dyskinetic action.

PMID: 16632329 [PubMed - indexed for MEDLINE]

Edited by Visionary7903, 18 June 2008 - 11:47 AM.

[Jacovis]

double post

Edited by Visionary7903, 18 June 2008 - 12:00 PM.

[smithx]

Why are you avoiding DHA?

Is there something wrong with it, or are you saying that only EPA matters?

[Jacovis]

Why are you avoiding DHA?

Is there something wrong with it, or are you saying that only EPA matters?

I am just trying to compile a thread of people's experiences with EPA-only formulas as DHA is said by some to decrease absorption of EPA. I personally take both but am interested in seeing what research and experiences there are out there supporting EPA-only formulas...

[Jacovis]

Some of the products with EPA-only formulas that qualify for this thread are as follows...

There is one other brand you forgot. I have been taking it for a year or so.

http://www.iherb.com...573725057314996

PlusEPA

90% EPA 500mg. per cap

Thanks ortcloud. Minami Nutrition's PlusEPA looks like exactly the kind of product this thread is all about:

Supplement Facts
Supplement Facts
Serving Size: 2 Softgels
Servings Per Container: 30
Amount Per Serving % DV
Calories 12
Calories from Fat 10
Total Fat 1.11 g 1.7%
Saturated fat 0 mg 0%
Cholesterol 0 mg 0%
Total Carbohydrate 0 g 0%
Total Protein 0.4 g 0.8%
Omega-3 Polyunsaturated Fat 1032 mg
EPA (Eicosapentaenoic Acid) 1000 mg †
DHA (Docosahexaenoic Acid) 0 mg †
Other Omega-3 Fatty Acids 32 mg †
Omega-6 Polyunsaturated Fat 32 mg †
Vitamin E (mixed tocopherols) 22 mg 146%
*Percent daily values based on 2,000 calorie diet.
†Daily value not established.

Other Ingredients
Pharmaceutical-grade deep-sea fish oil, hard capsule (gelatin, purified water, glycerol), Antioxidant (mixed tocopherols).

Pure and natural products without use of solvents or chemicals such as hexane.

The following reviews (for what their worth!) look ok as well for this product:
http://www.iherb.com...573725057314996
Works!, December 11, 2007
By Alex Epshteyn from United States NY
Love the stuff, never any taste and I can feel the difference after 2 weeks.
Note: iHerb does not imply any medical claims from this review. Disclaimer
ADHD, January 04, 2008
from United States CA
Works great ! Only product of its kind ! Highest EPA percentage ! There is a slight aftertaste, but not too much to make it a great concern. After trying many products of this kind, this is the best and they use a cold distillation process as opposed to exposing the product to high heat.
Note: iHerb does not imply any medical claims from this review. Disclaimer

http://www.amazon.co...3/dp/B000K7QJVW
Lynne, February 28, 2008
By Lynne E. Hogg (Orlando, Florida) - See all my reviews
This is an excellent product. My son has ADD Inattentive type and he takes 2 capsules every day, along with his medication, to improve his concentration. With the highest concentration of Omega 3, you will not find better.

More anecdotal experiences with PlusEPA...

http://www.itshealth...topic.php?t=113
wellhead (November 24, 2006):
"My son has ADHD and I want to up his doseage of EPA, I have not had his blood checked as yet but will do so. In the mean time I want to up his dosage using PlusEpa (Minami Nutrition, Belguim) to 100mg per capsule. I do not want to use ritalin or any other similar medication hence the MorEpa and the PlusEpa. he is being assisted at school with the special needs teacher and I will take it from there. Are there any other ways in which I can assist him in improving his situation.

Regards John"

drtom (November 25, 2006):
"My daughter actually takes PlusEPA , six capsules per day, for her ADHD. It has helped a lot and she has not had her blood checked, I have just titrated the dose up according to her response. My experience, both personal and professional, is that 2g of EPA ( four PlusEPA) is a good starting dose for most people. If the response is very poor, then you may need to do the blood test to see what is actually going on. It is important to limit trans fatty acids in the diet( crips, chips, cakes and general rubbish) as these will compete with the EPA at the cell membranes and reduce the impact of the dose. In some cases, sadly, stimulant medication is required but should be considered a last resort.
Pine bark extract has been touted as a possible herbal treatment for ADHD but I have no experience of this.

Dr Tom"

http://www.itshealth...topic.php?t=112
wellhead (December 10, 2006):
"Hi Dr,

I am now giving my son four of the PlusEpa a day for the last week or so and it seems to be helping..."

[Jacovis]

1: Aust N Z J Psychiatry. 2008 Mar;42(3):192-8.
Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.
Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H, Jalali M, Peet M.
Department of Nutrition and Biochemistry, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

OBJECTIVE: To compare therapeutic effects of eicosapentaenoic acid (EPA), fluoxetine and a combination of them in major depression. METHOD: Sixty outpatients with a diagnosis of major depressive disorder based on DSM-IV criteria and a score >or=15 in the 17-item Hamilton Depression Rating Scale (HDRS) were randomly allocated to receive daily either 1000 mg EPA or 20 mg fluoxetine, or their combination for 8 weeks. Double dummy technique was used to double blind the study. Patients were assessed at 2 week intervals. Change in HDRS was the primary outcome measure. RESULTS: Analysis of covariance for HDRS at week 8 across treatment groups was performed in 48 patients who completed at least 4 weeks of the study, with the last observation carried forward. Treatment, age of onset and baseline HDRS had a significant effect on HDRS at week 8. EPA + fluoxetine combination was significantly better than fluoxetine or EPA alone from the fourth week of treatment. Fluoxetine and EPA appear to be equally effective in controlling depressive symptoms. Response rates (>or=50% decrease in baseline HDRS) were 50%, 56% and 81% in the fluoxetine, EPA and combination groups, respectively. CONCLUSIONS: In the present 8 week trial EPA and fluoxetine had equal therapeutic effects in major depressive disorder. EPA + fluoxetine combination was superior to either of them alone.

PMID: 18247193 [PubMed - indexed for MEDLINE]